Matthew Barcus
Stock Analyst at Chardan Capital
(2.91)
# 1,655
Out of 4,735 analysts
23
Total ratings
21.74%
Success rate
20.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $14 → $12 | $1.79 | +570.39% | 2 | Nov 8, 2024 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $14.91 | +81.09% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $1.27 | +451.18% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $23.59 | +35.65% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $3.54 | +6,114.69% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.81 | +220.28% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $10.17 | -21.34% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.15 | +1,933.90% | 3 | Nov 17, 2022 |
Zura Bio
Nov 8, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $1.79
Upside: +570.39%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $14.91
Upside: +81.09%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $1.27
Upside: +451.18%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $23.59
Upside: +35.65%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $3.54
Upside: +6,114.69%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.81
Upside: +220.28%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $10.17
Upside: -21.34%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.15
Upside: +1,933.90%